VictorMedvil 307 Posted January 4 Report Share Posted January 4 (edited) It seems Uni-valent Retroviral Vector's Patents for usage in gene therapy have finally Expired, Link = (https://patents.google.com/patent/US6544771B1/en) The Patent over using Uni-Valent Retroviral Vectors with the VSV-G Gene Envelope is also Expired, Link = (https://patents.google.com/patent/US5817491A/en and https://patents.google.com/patent/US5512421A/en) Multivalent Viral Vector Production Patent is Expired, Link = (https://patents.google.com/patent/US20070218536A1/en and https://patents.google.com/patent/US20100203074A1/en) Multivalent Bacteriophage Production Patent is active held by Instytut Immunologii i Terapii Doswiadczalnej Until 2022 which is not expired, link = (https://patents.google.com/patent/US7232564B2/en) Multivalent Viral Vector's Patent is still active held by Janssen Vaccines and Prevention BV along with Aeras Global TB Vaccine Foundation until 2025 which is not expired, Link = (https://patents.google.com/patent/US8202723/de29) Cas9 Gene's Patent is active held by Massachusetts Institute of Technology and Broad Institute Inc until 2033 which is not expired, Link = (https://patents.google.com/patent/US8697359B1/en) Now selling Univalent VSV-G Retroviral Vectors for Gene Therapy! Multivalent Bacteriophages in 2022 and Multivalent Viral Vectors in 2025 along with Cas9 Insert Vectors in 2033. Edited January 6 by VictorMedvil Quote Link to post Share on other sites
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.